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ABSTRACT
Craniosynostosis describes conditions in which one or more sutures of the infant skull are prematurely fused, resulting in facial deformity
and delayed brain development. Approximately 20% of human craniosynostoses are thought to result from gene mutations altering
growth factor signaling; however, the molecular mechanisms by which these mutations cause craniosynostosis are incompletely
characterized, and the causative genes for diverse types of syndromic craniosynostosis have yet to be identified. Here, we show that
enhanced bone morphogenetic protein (BMP) signaling through the BMP type IA receptor (BMPR1A) in cranial neural crest cells, but not
in osteoblasts, causes premature suture fusion in mice. In support of a requirement for precisely regulated BMP signaling, this defect was
rescued on a Bmpr1a haploinsufficient background, with corresponding normalization of Smad phosphorylation. Moreover, in vivo
treatment with LDN-193189, a selective chemical inhibitor of BMP type I receptor kinases, resulted in partial rescue of craniosynostosis.
Enhanced signaling of the fibroblast growth factor (FGF) pathway, which has been implicated in craniosynostosis, was observed in
both mutant and rescued mice, suggesting that augmentation of FGF signaling is not the sole cause of premature fusion found in this
model. The finding that relatively modest augmentation of Smad-dependent BMP signaling leads to premature cranial suture
fusion suggests an important contribution of dysregulated BMP signaling to syndromic craniosynostoses and potential strategies
for early intervention.  2013 American Society for Bone and Mineral Research.
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Craniosynostosis, a syndrome of premature fusion of cranialsutures, affects 1 in 2500 live births.(1,2) This condition results
in facial deformity and restricted brain growth, with challenging
clinical management that often requires multiple corrective
surgeries. Individuals with craniosynostosis left untreated during
infancy develop increased intracranial pressure that can cause
chronic headaches and gradual loss of vision, and are at risk
for cognitive impairment. Craniofacial abnormalities seen with
craniosynostosis can also cause upper airway obstruction and
sleep apnea.(3)
Craniosynostosis is a devastating disorder, for which the only
treatment is carefully timed and extensive reconstructiveReceived in original form July 19, 2012; revised form November 19, 2012; accepte
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1422surgery. Although advances in molecular genetics in the past
decades have revealed several gene mutations that can result in
craniosynostosis, the molecular pathophysiology of craniosyn-
ostosis in humans remains incompletely understood. Limited
cases of syndromic craniosynostoses (20% to 30%) have been
found to be associated with the mutations of fibroblast growth
factor receptor family (FGFR1, FGFR2, and FGFR3), MSX2, TWIST1,
and EFNB1 in man; however, the genetic basis of most
craniosynostoses have yet to be identified.(1,2) Craniosynostosis
has diverse presentations, which include the Apert, Boston,
Crouzon, Pfeiffer, Jackson-Weiss, and Saethre-Chotzen syn-
dromes.(1,2) Although coronal sutures are commonly affected
in these syndromes, each syndrome has a unique pattern of
suture fusions. For example, the sagittal suture is frequentlyd December 5, 2012. Accepted manuscript online December 21, 2012.
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fused in both Crouzon and Pfeiffer syndromes but not in Saethre-
Chotzen syndrome. The unique pattern of fusion in each
syndrome suggests that distinct developmental processes
underlie various premature suture fusion phenotypes. Defining
the molecular and cellular pathogenesis of each syndromic
craniosynostosis could facilitate strategies for the early identifi-
cation, prevention, or treatment of these developmental defects.
Bone morphogenetic proteins (BMPs) play broad roles in
developmental patterning, including skull morphogenesis.(4–7)
Gain-of-functionmutations in MSX2, a member of the homeobox
gene family whose transcription is regulated by BMP and
TGF-b signaling, result in an autosomal dominant Boston-type
craniosynostosis in man, whereas mice overexpressingMsx2 also
develop premature fusion of coronal and sagittal sutures.(8,9)
Moreover, the endogenous BMP antagonist noggin is expressed
in nonfusing sutures and is observed to enforce suture patency
in mice.(10) These prior observations suggest that appropriate
levels of BMP signaling may be critical for maintaining normal
suture patency during skull development and that dysregulated
BMP signaling may contribute to craniosynostosis.
Because the frontal region of cranial bones and sutures are
derived from a distinct multipotent cell population, ie, cranial
neural crest (CNC) cells,(11–13) we hypothesized that aberrant
differentiation of CNC cells caused by alterations in BMP
signaling results in cranial malformations. To test this hypothesis,
we developed a conditional mouse model with enhanced BMP
signaling in the skull and sutures. We found that failure to
maintain precisely controlled Smad-dependent BMP signaling
in CNC cells but not in osteoblast-committed cells led to
craniosynostosis. We also found that reduction of BMP signaling
by genetic or pharmacological methods rescued the premature
fusion found in the metopic suture, as well as abnormalities
found in CNC-derived skull bones. In this enhanced BMP
signaling model, we also observed enhanced FGF ligand
expression. However, these perturbations in FGF signaling did
not appear to account for craniosynostosis, in contrast to the
phenotypes observed in FGF gain-of-functionmutant mice.(14–17)
These results lend novel mechanistic support for the concept
that supraphysiological levels of BMP signaling contribute to
some human craniosynostoses, which in turn might bemitigated
by pharmacologic blockade early in their genesis.
Materials and Methods
Generation of ca-Bmpr1a mouse lines
A plasmid containing human BMPR1A cDNA with a Q233D
mutation was kindly obtained from Dr T Imamura (Cancer
Institute of Japan). The cDNA fragment was inserted into a PstI
site of the CAG-Z-EGFP vector.(18,19) The transgenic vector was
linearized and electroporated into AB2.2 mouse ES cells (Lexicon
Genetics, The Woodlands, TX, USA) with a PGKneobpA plasmid
for selection with G418. Ninety-six G418-resistant colonies were
stained for b-gal activity to confirm the expression of the
transgene. Four representative ES clones, which showed
relatively strong expressions of b-gal activity, were injected
into blastocysts from C57BL/6 mice, and 3 of them (clones A3, F1,
and F2) underwent germline transmission. Progenies bred withJournal of Bone and Mineral Researchwild-type C57BL/6 showed expected ration of transmission of
the transgene (50%), indicating that transgenic mouse lines have
a single integration site for transgene in its genome. We initially
analyzed progenies from clone A3 and F1 to confirm that they
developed identical phenotypes (Supplemental Fig. S1), thus we
focused transgenic line from clone A3 in the rest of the analyses.
P0-Cre mouse, C57BL/6J-Tg(P0-Cre)94Imeg (ID 148), was provid-
ed by CARD, Kumamoto University, Japan. All mouse experi-
ments were performed in accordance with National Institute
of Environmental Health Sciences and University of Michigan
guidelines covering the humane care and use of animals in
research.
Histology, skeletal staining, immunohistochemistry and
micro-computed tomography (mCT)
Embryos were fixed in either 10% formalin or 4% paraformalde-
hyde, embedded in paraffin, and stained with hematoxylin and
eosin (H&E). Cranial bone was stained with alizarin red and alcian
blue by standard methods. For immunohistochemistry, mouse
skull was fixed with 4% paraformaldehyde at 48C overnight
and replaced with 20% sucrose in PBS at 48C. Samples were
embedded by OCT compound and 10-mm cryo-sections were
cut. After washing with PBS containing 0.1% Triton X-100, the
specimens were incubated with rabbit anti-FGF2 (dilution 1:100,
catalog number: AB1458, Chemicon, Billerica, MA, USA), rabbit
anti-FGFR1 (dilution 1:100, catalog number: sc-121, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit anti-FGFR2 (dilution
1:100, catalog number: sc-122, Santa Cruz), rabbit anti-phospho-
p38 MAPK (dilution 1:50, catalog number: 4631, Cell Signaling,
Billerica, MA, USA), and rabbit anti-phospho-SMAD1/5/8 (dilution
1:100, catalog number: 9511, Cell Signaling) at 48C overnight,
with Alexa Fluor 488 donkey anti-rabbit IgG (dilution 1:100,
catalog number: A21206, Invitrogen, Grand Island, NY, USA) used
as secondary Ab. Sections were mounted with ProLong Gold
antifade reagent with 4,6-diamidino-2-phenylindole (DAPI;
catalog number: P36935, Invitrogen). Fluorescence images were
obtained with an Olympus BX-51 microscope with an Olympus
DP-70 CCD camera. Captured images were processed in Adobe
Photoshop CS3 (version 10.0). Skulls were scanned using a mCT
system at 12mm of thickness, 55 kV of energy, and 145mA of
intensity (mCT40: Scanco Medical AG, Bru¨ttisellen, Switzerland),
and reconstructed to produce 2D and 3D images.(20)
Quantitative real-time RT-PCR
Skull tissues were pretreated with RNA later (Ambion, Grand
Island, NY, USA) and RNA isolated using TRIzol (Invitrogen).
cDNA was synthesized by using SuperScript III cDNA Synthesis
(Invitrogen). TaqMan probes were purchased and real-time
RT-PCR was performed by ABI PRISM 7500 (Applied Biosystems,
Grand Island, NY, USA). Data were normalized to GAPDH by
2DDCt method.
Establishment of preosteoblast cells from the skull
Cranial preosteoblasts were established from newborn pups as
described previously.(13,21) Preosteoblasts were grown in mini-
mum essential medium (alpha-MEM) (catalog number: 12561,BMP SIGNALING AND CRANIOSYNOSTOSIS 1423
Invitrogen) with 10% fetal bovine serum (Hyclone, Logan, UT,
USA) and penicillin/streptomycin (catalog number: P-0781,
Sigma, St. Louis, MO, USA). An amount of 100mg/mL ascorbic
acid (catalog number: A-4403, Sigma) and 4mM b-glyceropho-
sphate (catalog number: G-9891, Sigma) were added for further
primary cultures.
Cell culture and immunoblot analysis
Preosteoblasts were stimulated with recombinant human BMP2
(catalog number: 355-BM, R&D, Minneapolis, MN, USA) or FGF1
(catalog number: 232-FA, R&D) depending on each experimental
time course. RIPA buffer (20mM Tris-HCl, 0.1% SDS, 1% Triton
X-100, 1% sodium deoxycholate) was used for preparation of cell
extracts. Subsequently, cell lysates were separated by SDS-PAGE
and transferred to Amersham Hybond-P membrane (GE
Healthcare, Pittsburgh, PA, USA). Immunoblotting was per-
formed with rabbit anti-phospho-SMAD1/5/8 (9511), rabbit anti-
phospho-p44/42 MAPK (ERK1/2) (4376), rabbit anti-p44/42 MAP
Kinase (4695), rabbit anti-phospho-p38 MAPK (4631), rabbit anti-
p38 MAP Kinase (9212), rabbit anti-phospho-SAPK/JNK (4668),
rabbit anti-SAPK/JNK (9258), rabbit anti-phospho-TAK1 (9399),
and rabbit anti-TAK1 (4505), all from Cell Signaling. Mouse anti-b
actin (catalog number: A-5441, Sigma) and rabbit anti-GAPDH
(catalog number: 2118, Cell Signaling) were used as a loading
control. Signal detection was performed by ECL Western blotting
detection reagents (GE Healthcare).
Treatment of animals with aqueous LDN-193189
LDN-193189 was dissolved in sterile endotoxin-free water.(22) A
dose of 2.5mg of the LDN-193189 per kg body weight per day
was injected intraperitoneally into pregnant mice on days E14
through E18 and continued through P15 to nursing dams.Fig. 1. Enhanced BMP signaling through constitutively active form of Bmpr1a
broad snouts and hypertelorism at P17. (E, F) Skeletal staining at P17 revealed
(F; white arrows), whereas AF suture in controls was still patent (E; white arrow
frontal bones (black dots). (G, H) H&E staining was performed on histological
although AF suture in control showed patency (G; red arrows). The thickness o
suture; F¼ frontal bone; N¼nasal bone; PF¼ posterior frontal suture.
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Generation of constitutively active form of Bmpr1a mice
and validation of neural crest-specific Cre mice
To target enhanced BMP signaling to the CNC cells, we
generated transgenic mice that conditionally express a consti-
tutively active form of Bmpr1a (ca-Bmpr1a) (Supplemental Fig.
S2A). A mutation of Gln residue 233 to Asp (Q233D) of the
glycine-serine (GS)–rich kinase regulatory domain of Bmpr1a is
known to result in constitutive activation of the type I receptor
kinase activity.(23) We bred these mice with P0-Cre mice, which
express a Cre-recombinase transgene under control of a neural
crest-specific promoter.(24) This genetic manipulation enhances
BMP signaling specifically in neural crest-derived tissues. We
confirmed localization of P0-Cre-expressing cells in the skull
using ROSA26 reporter line(25) (Supplemental Fig. S3). LacZ-
positive cells were observed in nasal-frontal bones and the
metopic suture as expected,(11) consistent with efficient target-
ing of CNC-derived cells by the P0-Cre transgene during skull
development.
Enhanced BMP signaling through ca-BMPR1A in cranial
neural crest cells causes craniosynostosis
The mutant mice, which carried both ca-Bmpr1a and P0-Cre
transgenes (ca-Bmpr1a:P0-Cre, or mutant [MT], hereafter),
showed enhanced levels of SMAD1/5/8 phosphorylation without
ligand stimulation in CNC-derived preosteoblast cells from
skull that were further increased by BMP2 ligand treatment
(Supplemental Fig. S2B). These mutant mice displayed short,
broad snouts and orbital hypertelorism (Fig. 1A–D). Skeletal
staining at postnatal day 17 (P17) and histological observation at
P8 revealed premature fusion of the anterior frontal (AF) suture in
ca-Bmpr1a:P0-Cre, whereas AF sutures in control mice retainedcauses craniosynostosis. (A–D) Ca-Bmpr1a:P0-Cre (MT) displayed short,
premature fusion in AF suture. AF suture was fused in ca-Bmpr1a:P0-Cre
s). Along with premature fusion, foramina were developed in mutant’s
specimen at P8. AF suture in mutants displayed premature fusion (H),
f mutant skull was thinner than control (black lines). AF¼ anterior frontal
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patency (Fig. 1E–H). Other sutures including the coronal suture
developed normally (Supplemental Fig. S4), and no bones were
missing in skull base of mutant mice (Supplemental Fig. S5).
Calvaria from ca-Bmpr1a:P0-Cre were thinner (Fig. 1G, H),
resembling a phenotype found in a mouse model of Apert
syndrome harboring a mutation in Fgfr2 (Ser252Trp) represent-
ing one of the most severe forms of craniosynostosis.
Interestingly, we found evidence of increased apoptosis in
mutant mice at newborn stage (Supplemental Fig. S6),
consistent with the thin calvaria found in ca-Bmpr1a:P0-Cre
(Fig. 1G, H) and in certain syndromes such as Apert-type
craniosynostosis.(21,26–30)
Because our mutant mice showed increased levels of Smad
signaling in neural crest-derived tissues including osteoblasts,
one of the immediate hypotheses to be examined is that the
enhanced BMP signaling in differentiated osteoblasts stimulates
their proliferation and/or differentiation to ossify suture
mesenchyme. Thus, first we investigated the proliferative and
differentiation capability of the mutant osteoblasts. However,
there were no significant differences in the ability of
skull-derived preosteoblasts to proliferate or differentiate
(Supplemental Fig. S7). Next, we bred ca-Bmpr1a mice with
Col1-CreERTM (ca-Bmpr1a:Col1-CreERTM)(31) to activate BMP
signaling in an osteoblast-specific manner to examine if
enhanced BMP signaling through BMPR1A exerts its effects
through osteoblast-lineage committed cells during skull
development. Although Col1-CreERTM showed the robust
Cre recombination in whole skull in our previous study,(31)
ca-Bmpr1a:Col1-CreERTM mice did not display any of the skull
abnormalities seen in ca-Bmpr1a:P0-Cre mice (Supplemental
Fig. S8). Such striking phenotypic differences between neural
crest-specific and osteoblast-specific activation of BMP signaling
reveal the critical role of BMP signaling in neural crest-derived
multipotent cells rather in the osteoblast-committed lineages
for governing normal skull development by regulating suture
patency.
FGF components and FGF signaling are upregulated in
enhanced BMP signaling mutants
Because upregulated FGF signaling results in craniosynosto-
sis,(15,16,32–34) as exemplified by Apert syndrome,(14,17,35) we
speculated that enhanced BMP signaling through BMPR1A
might positively regulate FGF signaling or components of its
pathway leading to premature suture fusion. We first analyzed
the expression of FGF pathway components in the skull by
immunohistochemistry at embryonic day (E) 17.5. In the AF
sutures of mutant embryos, levels of FGF2, FGFR1, and FGFR2
were significantly upregulated (Fig. 2A). Consistent with the
upregulation of FGF ligand and receptors in mutant embryos,
phosphorylated ERK1/2 (p-ERK1/2), a known effector of FGF
signaling, was dramatically increased in mutant skull bones and
metopic sutures (Fig. 2B). Using preosteoblasts established from
CNC-derived skull bones (nasal and frontal), we observed that
higher levels of p-ERK1/2 were induced with BMP2 stimulation in
mutant preosteoblasts compared with control preosteoblasts
(Fig. 2C, D). Taken together, these results suggest that enhanced
BMP signaling through BMPR1A in CNC cells might upregulate orJournal of Bone and Mineral Researchsynergize with FGF signaling to promote craniosynostosis, which
we examined further as below.
Augmentation of FGF signaling is not the direct cause to
develop skull malformation in enhanced BMP signaling
mutants
To help confirm that the ca-Bmpr1a transgene exerted its
effects on both skull and suture abnormalities via excess
BMP signaling, we tested the impact of decreased wild-type
Bmpr1a gene dosage by superimposing Bmpr1a heterozygosity
(Bmpr1aþ/)(36) on the ca-Bmpr1a:P0-Cre double transgenic
background. Notably, ca-Bmpr1a:P0-Cre carrying one copy of
endogenous Bmpr1a (ca-Bmpr1a:P0-Cre:Bmpr1aþ/, rescued; R,
n¼ 7) showed normal head morphology that was comparable
with controls (control; CT, n¼ 7), whereas ca-Bmpr1a:P0-Cre
littermates with two copies of endogenous Bmpr1a retained the
craniosynostosis phenotype (mutant; MT, n¼ 7) (Fig. 3A). We
confirmed the patency of AF sutures in rescued mice by skeletal
staining and histological analysis (Fig. 3A). We also noted that
skull bone thickness in rescued mice was comparable to that
of control mice (Fig. 3A). We further examined the expression
level of Bmpr1a among control, ca-Bmpr1a:P0-Cre and
ca-Bmpr1a:P0-Cre:Bmpr1aþ/ preosteoblast cells by quantitative
real-time RT-PCR (qRT-PCR). Bmpr1a expression was reduced by
more than half in ca-Bmpr1a:P0-Cre:Bmpr1aþ/ cells compared
with both control and ca-Bmpr1a:P0-Cre preosteoblast cells
(Fig. 3B). Expression levels of the transgene were very low when
assessed using transgene-specific primers by qRT-PCR (data not
shown), explaining the observation that levels of Bmpr1a
expression in the mutants (when measuring transcripts both
from the endogenous locus and the transgene) were comparable
with those in controls. These results demonstrate that the
increase in BMP signaling mediated by ca-Bmpr1a transgene is
relatively modest in that the loss of one wild-type allele may
compensate, and consequently that precise regulation of BMP
signaling is critical for maintaining suture patency and normal
skull morphogenesis.
Because FGF signaling was also upregulated in mutant skulls
(Fig. 2), we speculated that increased BMP signaling in CNC cells
might enhance FGF signaling to cause premature suture fusion in
ca-Bmpr1a:P0-Cre mice. To compare the regulation of FGF
signaling molecules in normal and mutant skulls, we examined
their levels of expression in nasal-frontal bones by qRT-PCR. On
one hand, the expression of Fgf2, Fgfr1, Fgfr2, components for
the FGF signaling, and Sprouty1/2/3/4, downstream targets for
the FGF signaling, in mutant (MT) mice were enhanced
compared with control (CT) mice (Fig. 3C), suggesting enhanced
FGF signaling accompanies enhanced BMP signaling in this
model. However, the expression of these genes was comparable
between MT and rescued (R) mice (Fig. 3C). Furthermore, we
found comparable levels of p-ERK1/2 in MT and R preosteoblasts,
which still showed a higher degree of ERK1/2 activation
compared with control (CT) preosteoblasts (Fig. 3D). These
results suggest that the rescue of the craniosynostosis
phenotype in compound inducible-transgenic and haploinsuffi-
cient mice was not the result of the normalization of FGF-ERK1/2
signaling.BMP SIGNALING AND CRANIOSYNOSTOSIS 1425
Fig. 2. Enhancement of BMP signaling results in upregulation of FGF ligand, receptors, and phospho-ERK1/2. (A) Immunohistochemistry was performed
by using FGF2, FGFR1, and FGFR2 antibodies (green) at E17.5. Levels of FGF2, FGFR1, and FGFR2were upregulated in anterior frontal suture and osteoblasts
in ca-Bmpr1a:P0-Cre (MT). (B) The levels of phospho-ERK1/2 (P-ERK1/2) in ca-Bmpr1a:P0-Cre at E17.5 were highly activated compared with controls (CT).
Osteogenic front is marked by the white asterisk. (C) Kinetics of ERK1/2 pathway activation after BMP2 stimulation. Preosteoblasts were stimulated with
recombinant BMP2 (100 ng/mL) for the time indicated (minutes). Levels of P-ERK1/2 along with levels of total ERK1/2 proteins were measured by Western
blotting. Peak and sustained levels of P-ERK1/2 in ca-Bmpr1a:P0-Cre preosteoblasts were much higher than in control preosteoblasts. (D) Results in C for
P-ERK1/2 quantified by densitometry.Enhanced Smad-dependent BMP signaling pathway is
responsible for the etiology of craniosynostosis
Upregulated FGF/ERK signaling did not appear to account for
skull development abnormalities observed in ca-Bmpr1a:P0-Cre
mice (Fig. 3C, D). We investigated other potential explanations of
how enhanced Smad-dependent or -independent BMP signaling
might induce premature suture fusion in mutants via down-
stream intracellular signaling. We assessed activation of other
mitogen-activated protein kinase (MAPK) pathways including
p38, which are thought to be effectors of Smad-independent
signaling by BMP and TGF-b ligands.(37) Consistent with findings
of enhanced Smad activation in skull-derived preosteoblasts
(Supplemental Fig. S2B), mutant calvarium exhibited higher
levels of phosphorylated SMAD1/5/8 (p-SMAD1/5/8) compared
with controls (Fig. 4A). On the other hand, levels of
phosphorylated p38 (p-p38) remained undetectable in both
control and mutant skulls (Fig. 4A). In addition, BMP2 stimulation
did not activate p38 or JNK beyond basal levels in skull-derived
preosteoblasts (Fig. 4B). Moreover, levels of phosphorylated
TGF-b-activated kinase 1 (TAK1), the MAPKKK functioning
upstream of p38 and JNK,(38) was comparable between control,1426 KOMATSU ET AL.mutant, and rescued preosteoblast cells (Supplemental Fig. S9).
The lack of modulation of TAK1 or specific MAPK pathways in
mutant mouse tissues suggested that canonical Smad-depen-
dent BMP signaling may be primarily responsible for the
craniosynostosis phenotype. To investigate further the relation-
ship between enhanced Smad-dependent BMP signaling and
skull defects in ca-Bmpr1a:P0-Cre, we examined the kinetics of
p-SMAD1/5/8 signaling in control, mutant, and rescued
preosteoblasts. As seen in the mutant calvarium showing
enhanced SMAD1/5/8 phosphorylation (Fig. 4A), MT preosteo-
blasts displayed the higher basal levels of p-SMAD1/5/8 (at 0
minutes) and greater levels of p-SMAD1/5/8 in response to BMP2,
which were restored in R presosteoblasts to levels comparable to
CT preosteoblasts (Fig. 4C, D). These findings strongly suggest
that enhanced Smad-dependent BMP signaling is the principal
etiology of craniosynostosis in ca-Bmpr1a:P0-Cre mice.
Treatment of selective chemical inhibitor of BMP type I
receptor kinases partially rescues craniosynostosis
phenotype in vivo
To assess further the role of enhanced Smad-dependent BMP
signaling in the skull malformation phenotype, we used aJournal of Bone and Mineral Research
Fig. 3. Heterozygous mutation of Bmpr1a rescues the phenotype of craniosynostosis. (A) Heterozygous null mice for Bmpr1a also expressing a P0-Cre
transgene were crossed with ca-Bmpr1a-transgenic mice. Heterozygosity of Bmpr1a rescued morphological abnormalities of craniofacial region
developed in ca-Bmpr1a:P0-Cre. Skeletal staining was performed for skulls. Skull bone shapes were similar between both control (CT) and
ca-Bmpr1a:P0-Cre carrying heterozygous null Bmpr1a (R). Patency of anterior frontal suture was confirmed by histological analysis. Red arrows indicated
anterior frontal suture in control (CT) and ca-Bmpr1a:P0-Cre carrying heterozygous Bmpr1a (R). Note that bone thickness and foramen in frontal bone were
also recovered in rescued skull (R) (black lines). (B) Expression of Bmpr1a was measured by quantitative real-time RT-PCR (qRT-PCR) in preosteoblast cells
from CNC-derived skull tissues. Open columns (control; CT), black columns (ca-Bmpr1a:P0-Cre; MT), and gray columns (ca-Bmpr1a:P0-Cre carrying
heterozygous null Bmpr1a; R) were shown, respectively. Data presented were means SEM by three different preosteoblast cells from skull and three
independent experiments. p< 0.05. (C) Expression of FGF ligand (Fgf2), receptors (Fgfr1, Fgfr2) and downstream targets (Sprouty1, 2, 3, 4) were measured
by qRT-PCR in nasal and frontal bones at P4. Open columns (control; CT), black columns (ca-Bmpr1a:P0-Cre; MT), and gray columns (ca-Bmpr1a:P0-Cre
carrying heterozygous null Bmpr1a; R) were shown, respectively. Data presented were means SEM by three different skulls and three independent
experiments. p< 0.05. (D) Preosteoblasts from the skull were stimulated with recombinant BMP2 (100 ng/mL) and levels of phospho-ERK1/2 (P-ERK1/2)
along with levels of total ERK1/2 proteins were measured by Western blotting. The levels of P-ERK1/2 were still comparable between mutants
(ca-Bmpr1a:P0-Cre) and rescued (ca-Bmpr1a:P0-Cre carrying heterozygous null Bmpr1a).selective chemical inhibitor for BMP type I receptor kinases,
LDN-193189,(22,39) as a means for normalizing Smad-dependent
signaling. Because LDN-193189 and other chemical kinase
inhibitors are known to possess various off-target effects,(40) we
validated the selectivity of LDN-193189 for Smad-dependent
BMP signaling in our tissues. We measured levels of p-SMAD1/5/8
with varying concentrations of LDN-193189 using wild-type
preosteoblasts from neural crest-derived bones in skull. Similar
to what was previously reported,(22) in skull-derived preosteo-
blasts low concentrations of LDN-193189 (50 nM) were
sufficient to inhibit BMP-mediated phosphorylation of SMAD1/
5/8 without affecting Smad-independent signaling pathways
(Fig. 5A, left panel). We further examined the potential impact of
LDN-193189 upon levels of p-TAK1, p-ERK1/2, and p-p38 induced
by FGF stimulation (Fig. 5A, right panel), confirming the activityJournal of Bone and Mineral Researchof LDN-193189 as a selective inhibitor of Smad-mediated BMP
signaling in CNC-derived preosteoblasts. We next explored the
efficacy of LDN-193189 in the prenatal prophylaxis of craniosyn-
ostosis in ca-Bmpr1a:P0-Cre. LDN-193189 was administered
(2.5mg/kg per day ip) to pregnant ca-Bmpr1a females after
timed mating with P0-Cre males starting at E14.5 (Fig. 5B). After
birth, lactating dams continued to receive LDN-193189 through
P15, and neonates were euthanized at P16. Importantly, the
cranial morphology of ca-Bmpr1a:P0-Cre treated in utero and
perinatally with LDN-193189 was normalized (Fig. 5C). The length
of nasal bones (n¼ 5/6) and the shape of foramina in frontal
bones (n¼ 3/6) were normalized to that of control mice.
Interestingly, prenatal LDN-193189 treatment did not visibly
affect normal skull development in control pups (n¼ 6/6)
(Fig. 5C). Bone volume and trabecular number were decreasedBMP SIGNALING AND CRANIOSYNOSTOSIS 1427
Fig. 4. Enhanced Smad-dependent BMP signaling is responsible for developing craniosynostosis. (A) Immunohistochemistry using phospho-Smad1/5/8
(P-SMAD1/5/8) and phospho-p38 (P-p38) antibodies (green) were performed for calvarial sections at E17.5. Samples were counterstained with DAPI (blue).
Osteogenic front is marked by the white asterisk. (B) Kinetics of MAPK pathways activation after BMP2 stimulation in preosteoblasts of control (CT)
and mutant (ca-Bmpr1a:P0-Cre; MT). Preosteoblasts were stimulated with recombinant BMP2 (100 ng/mL) for the time indicated (minutes). Levels of
phospho-P38 (p-P38) and phospho-JNK (p-JNK) along with levels of total MAPK proteins were measured by Western blotting. (C) Phospho-Smad1/5/8
(P-SMAD1/5/8) levels were examined in preosteoblasts of control (CT), mutant (ca-Bmpr1a:P0-Cre; MT) and rescued (ca-Bmpr1a:P0-Cre carrying
heterozygous null Bmpr1a; R). Preosteoblasts were stimulated by recombinant BMP2 (100 ng/mL) for indicated time (minutes) then P-SMAD1/5/8 levels
were examined by Western blotting. GAPDH was used as a loading control (upper panel). (D) Results for P-SMAD1/5/8 from C were quantified by
densitometry (lower panel).and trabecular spaces were wider in nasal and frontal bones of
ca-Bmpr1a:P0-Cre but were also normalized after LDN-193189
treatment (Fig. 5D). These results demonstrate that prenatal and
perinatal treatment with a selective chemical inhibitor of BMP
type I receptor kinases can partially rescue craniosynostosis in
vivo, further supporting the importance of precisely regulated
Smad-signaling in this phenotype.
Discussion
Our genetic study demonstrates that tightly controlled levels of
Smad-dependent BMP signaling through BMPR1A in CNC cells,
not in committed osteoblasts, are critical for regulating suture
patency and normal skull morphogenesis, whereas excessive
signaling leads to craniosynostosis. Underneath molecular
mechanisms of our findings are summarized in Fig. 6. In wild-
type, BMPR1A exerts both Smad-dependent and -independent
signaling upon BMP ligand binding. In the mutant mice
(ca-Bmpr1a:P0-Cre), the basal levels of Smad-dependent signal-
ing are upregulated and further increased upon BMP ligand
binding. Increases of p-ERK1/2 are also observed, not because of
the increase of Smad-independent signaling mediated by TAK1,
but because of the increase of FGF signaling (Supplemental Fig.1428 KOMATSU ET AL.S9). In the rescued mice (ca-Bmpr1a:P0-Cre:Bmpr1aþ/), removal
of one copy of endogenous Bmpr1a normalizes levels of Smad-
dependent signaling, leading to the phenotypic rescue of suture
patency and skull morphology. Enhanced levels of FGF-ERK
signaling are still observed in the rescued mice. There are two
outstanding questions why Smad-signaling enhanced by the
constitutively activated BMPR1A is normalized by removal of one
copy of the endogenous gene and why FGF signaling is still
augmented in the rescued samples (see below for potential
explanations). Although additional studies are necessary to
answer these questions, our current results clearly demonstrate
that a modest increase of BMP signaling via Smad-dependent
signaling in CNC cells can be a cause of a premature suture fusion
in our mouse model.
There is overwhelming evidence both in humans and mice
that enhanced FGF signaling contributes to several types of
craniosynostosis.(1,2,41,42) Our mutant mice also exhibit upregu-
lated FGF signaling; however, our model appears to be unique in
that the enhanced levels of FGF signaling observed do not
appear to be sufficient for the phenotype. Rather, the
independent contribution of Smad-dependent BMP signaling
in our model suggests an important and novel signaling
mechanism for the etiology of craniosynostosis. Because
associated gene mutations are identified in only 20% to 30%Journal of Bone and Mineral Research
Fig. 5. BMP type I receptor-specific chemical inhibitor LDN-193189 partially recovers the craniosynostosis phenotype in vivo. (A) Wild-type preosteoblasts
from skull were pretreated with LDN-193189 (0.005mM to 20mM) for 30 minutes. Subsequently, preosteoblasts were stimulated by either BMP2 or FGF1
recombinant (100 ng/mL) for 10 minutes. Levels of phospho-Smad1/5/8 (P-SMAD1/5/8), phospho-ERK1/2 (P-ERK1/2), phospho-p38 (P-p38), and phospho-
TAK1 (P-TAK1) were examined by Western blotting. GAPDH was used as a loading control. (B) Schematic representation of the dosing and harvesting
schedule of LDN-193189 in vivo. (C) Lateral and top view of face in control (CT) and ca-Bmpr1a:P0-Cre (MT) treated with LDN-193189. Note that short, broad
snouts and hypertelorism in ca-Bmpr1a:P0-Cre were partially recovered, which was comparable to the control mice. (D) Bone volume (BV/TV), trabecular
number (Tb.N), and trabecular spaces (Tb.Sp) in nasal and frontal bones were quantified by mCT. Data presented were means SD by three different skulls
and three independent experiments. p< 0.05, p< 0.005.of human craniosynostosis(1,2) and each case shows diverse
phenotypes such as positions of premature fusions and thickness
of calvaria,(26,35) some of the human cases may be developed by
mutations in other signaling cascade than FGF signaling. Our
findings suggest one of the possibilities that some of the human
craniosynostosis are caused by misregulation of BMP signaling.
Because enhanced production of FGF ligands and receptors
and consequent activation of ERK1/2 are the causes of Apert
syndrome,(15–17,34) it is surprising that our compound transgenic/
haploinsufficient mice exhibited upregulated FGF signaling in
the face of essentially complete phenotypic rescue (Fig. 3B, C).
One explanation may be that enhanced FGF signaling in ca-
Bmpr1a:P0-Cre mice is not sufficient to induce morphological
malformations, ie, FGF signaling in ca-Bmpr1a:P0-Cre does not
attain levels needed to develop craniosynostosis, as seen in
Fgfr2þ/S252Wmice, for example.(17) However, it is possible that the
enhanced FGF signaling activity found in ca-Bmpr1a:P0-Cre mice
may enhance pathogenesis of skull deformity but only in the
context of sufficient BMP signaling. Although the mechanism ofJournal of Bone and Mineral Researchhow enhanced BMP signaling upregulates the expression of FGF
ligand, receptors and downstream components in mutant skulls
is unclear, it has been reported that FGF receptor genes have Sp1
and Ap1 binding sequences in their promoters.(43,44) Deletion of
the Ap1 promoter sequence from a TGF-b and BMP-inducible
gene disrupts BMP and TGF-b responsiveness,(45) suggesting
BMP signaling might regulate FGF via the Sp1/Ap1 promoter
sequences. Thus, one could postulate that enhanced Smad-
dependent BMP signaling may induce Sp1/Ap1 family transcrip-
tional regulators that will bind to promoters of FGF receptors to
enhance their expression in ca-Bmpr1a:P0-Cremice. Subsequent-
ly, phospho-ERK1/2 may be evoked through the augmentation
of FGF signaling in ca-Bmpr1a:P0-Cre mice. Further studies
investigating the overlay of genetic or pharmacologic suppres-
sion of FGF signaling in our model would help to resolve this
possibility.
The simplistic notion that excessive FGF-mediated signaling
and cell growth drives the pathophysiology of craniosynostosis is
complicated by the fact that craniosynostoses with enhancedBMP SIGNALING AND CRANIOSYNOSTOSIS 1429
Fig. 6. A mechanism by which enhanced BMP signaling develops craniosynostosis in mice. In wild-type skull, BMPR1A (green) exerts both Smad-
dependent and -independent signaling upon ligand binding (left panel). In the mutant mice (ca-Bmpr1a:P0-Cre), which has a constitutively active form of
BMPR1A (purple), basal levels of Smad-dependent signaling are upregulated and it is further increased upon ligand binding. Increases of phospho-ERK1/2
are also observed because of the increase of FGF signaling (middle panel). In the rescued mice (ca-Bmpr1a:P0-Cre:Bmpr1aþ/), removal of one copy of
endogenous BMPR1A normalizes levels of Smad-dependent signaling, leading to the phenotypic rescue of premature suture fusions and skull
morphology (right panel). Enhanced levels of FGF-ERK signaling are still observed in the rescued mice, but it may be not sufficient to induce
morphological malformations, ie, FGF signaling in ca-Bmpr1a:P0-Cre:Bmpr1aþ/ mice does not attain levels needed to develop craniosynostosis
(see Discussion).FGF signaling are not always marked by enhanced proliferation
and differentiation. Specifically, the FGFR2 C342Y mutation
(Crouzon-type craniosynostosis) inhibits preosteoblast differen-
tiation and increases apoptosis in vitro.(21) Moreover, Deng and
colleagues found that the FGFR2 S252W mutation results in
Apert-type craniosynostosis in mice but did not observe changes
in cell differentiation and proliferation, concluding that
dysregulated apoptosis is involved in the pathogenesis of
Apert-type skull defects,(26) consistent with our observations
(Supplemental Fig. S5). These observations and the present study
support the concept that clinical phenotypes of craniosynostosis
are quite divergent and cannot be accounted for by a single
mechanism.
Craniosynostosis in ca-Bmpr1a:P0-Cre could be rescued by the
loss of a single endogenous Bmpr1a allele (Fig. 3), suggesting
that a relatively small increment in levels of Smad-signaling
results in the mutant phenotype, despite the use of an
overexpressed and constitutively-active Bmpr1a transgene.
Expression levels of ca-Bmpr1a transgene were quite low when
assessed by qRT-PCR (data not shown), which may lead to the
very modest increase of signaling associated with transgene. The
completeness of rescue by heterozygosity and the mildly
enhanced ligand-independent and ligand-dependent BMP
signaling observed in the tissues of these mice and with
other constitutively active BMP type I receptor transgenes(22,46)
suggest that the levels of BMP signaling attained by these1430 KOMATSU ET AL.strategies are only mildly supraphysiologic. The results from our
pharmacological rescue also support this notion because the
dose of LDN-193198 that did not influence skull morphology in
the controls was capable of rescuing the craniosynostotic
phenotypes in the mutants (Fig. 5). Substantially larger increases
in BMP signaling, especially during embryogenesis, lead to
devastating outcomes.(18,47) In contrast, constitutively activating
GS domain mutations of the BMP type I receptor ACVR1 found in
fibrodysplasia ossificans progressiva(48) permit survival to term
with only mild morphological abnormalities, likely as a result of
mildly increased activity of mutant protein expressed under
endogenous promoter control.(49) We interpret these data to
suggest that moderate increases in BMP signaling, for example
caused by mutations in enhancer regions, could lead to
craniosynostosis in the appropriate context, a possibility that
has yet to be investigated in human studies. One interesting
issue that remains to be addressed is whether the phenotypic
rescue by heterozygosity of Bmpr1a is because of cell
autonomous or non-cell autonomous effects. Using Wnt1-Cre,
it was reported that nearly all cells in nasal and frontal bones are
derived from CNC cells during skull development.(2,11,13)
Similarly, as shown in Supplemental Fig. S3, we confirmed that
P0-Cre, which we used in our study, could efficiently and
specifically target to the CNC-derived cells in skull. We expect
that in ca-Bmpr1a:P0-Cre:Bmpr1aþ/ mice, virtually all cells
in nasal and frontal bones in addition to the metopic sutureJournal of Bone and Mineral Research
possess a constitutively active Bmpr1a transgene along with loss
of one allele of Bmpr1a. Thus, we are speculating that the skull
abnormalities were rescued in a cell autonomous manner.
Both Smad-dependent and -independent BMP signaling
pathways orchestrate cell fate, proliferation, and differentiation
in many tissues. Previous studies show that BMP signaling is
critical for skull development.(5,6,10,50–52) However, molecular
mechanisms by which Smad-dependent and/or -independent
BMP signaling regulate cranial development remain unknown.
Regarding Smad-independent BMP signaling pathway,
X-chromosome-linked inhibitor of apoptosis protein (XIAP)
bridges BMPR1A and TAK1 and induces the activation of MAPK
including p38.(53,54) One might hypothesize that augmentation
of BMP signaling via ca-BMPR1A modulates TAK1 activity, which
subsequently activates MAPK signaling pathway to cause
craniosynostosis. However, we did not observe significant
activation of TAK1 or MAPK p38 in mutant preosteoblasts
(Supplemental Fig. S9). The absence of modulation of TAK1
strongly argues against a role of MAPKs including p38 and JNK
in our model; however, we cannot fully exclude the participation
of other Smad-independent pathways contributing to the
Bmpr1a:P0-Cre phenotype.
It has been known that FGFR tyrosine kinase inhibitors
including PD173074 and PLX052 significantly prevent the
premature suture fusion in organ culture level,(16,55) and ERK/
MAPK specific blocker U0126 successfully inhibits craniosynos-
tosis in Fgfr2þ/S252W mice.(17) However, there are no known
therapeutic interventions for other mechanisms of craniosynos-
tosis. Because craniosynostoses have very diverse phenotypes
(and likely mechanisms), successful strategies would identify
chemopreventive reagents that target the specific etiology of
each type of craniosynostosis. Our study employing a selective
chemical inhibitor of BMP type I receptor kinases suggests a
potential therapeutic strategy for prophylaxis of craniosynostosis
caused by enhanced BMP signaling. Although it has not yet been
reported whether mutation(s) of BMPRIA cause craniosynostosis
in human, our results suggest that treatment of LDN-193189
might be useful in craniosynostosis that is either caused by or
facilitated by gain-of-function in BMP signaling. Identification of
mutations or biomarkers signifying enhanced BMP signaling
in CNC-derived tissues corresponding with syndromic or
nonsyndromic craniosynostosis would permit novel strategies
for early identification and intervention for this challenging and
incompletely characterized set of conditions.
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